Article Text

other Versions

Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead-the response
  1. Rui Providência1,2,
  2. Jean-Paul Albenque1,
  3. Eloi Marijon3,4,
  4. Serge Boveda1
  1. 1Département de Rythmologie, Clinique Pasteur, Toulouse, France
  2. 2Faculty of Medicine, University of Coimbra, Coimbra, Portugal
  3. 3Heart Institute, Cedars Sinai Medical Center, Los Angeles, USA
  4. 4Paris Cardiovascular Research Center, Paris, France
  1. Correspondence to Dr Rui Providência, Département de Rythmologie, Clinique Pasteur, 45 avenue de Lombez, BP 27617, 31076 Toulouse Cedex 3, France; rui_providencia{at}

Statistics from

The Authors' reply We have read with interest the comments by Bin Abdulhak and colleagues1 to our recently published article.2 We share the same opinion concerning the use of dabigatran in this setting. Thus, in our article we have proposed the same posology in face of the similar findings: despite the lack of conclusive evidence in support of any particular dabigatran dosage or timing for interrupting or restarting drug therapy, like Bin Abdulhak and colleagues,1 we …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles